造血干细胞移植后高危骨髓增生异常综合征 - Suppr

Suppr

超能文献

High-risk MDS after HMAs.

作者信息

Adès Lionel

机构信息

Hopital Saint Louis, Paris, France.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000219. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000219

PMID:35309800

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925703/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4339/8925703/8075033e5bc9/hs9-3-0138-g001.jpg

相似文献

High-risk MDS after HMAs.造血干细胞移植后高危骨髓增生异常综合征

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000219. eCollection 2019 Jun.

Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs.RUNX1和ASXL1突变同时出现是接受HMA治疗的MDS患者反应不佳和预后不良的基础。

Am J Transl Res. 2019 Jun 15;11(6):3651-3658. eCollection 2019.

Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.新型低甲基化药物治疗骨髓增生异常综合征的治疗策略。

Int J Clin Oncol. 2014 Feb;19(1):10-5. doi: 10.1007/s10147-013-0651-5. Epub 2013 Dec 20.

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter.去甲基化剂的作用机制：以内源反转录元件为核心

Front Oncol. 2021 Mar 9;11:650473. doi: 10.3389/fonc.2021.650473. eCollection 2021.

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.老年骨髓增生异常综合征患者中低甲基化药物的使用模式。

Leuk Res. 2011 Jul;35(7):904-8. doi: 10.1016/j.leukres.2010.10.007. Epub 2010 Nov 9.

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.去甲基化药物在骨髓增生异常综合征治疗中的临床影响

Curr Pharm Des. 2016;22(16):2349-57. doi: 10.2174/1381612822666160310145040.

Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.针对低危骨髓增生异常综合征患者，在病例匹配队列中，使用去甲基化药物治疗可改善长期预后。

Ann Hematol. 2018 Dec;97(12):2309-2317. doi: 10.1007/s00277-018-3458-7. Epub 2018 Aug 2.

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.去甲基化药物与免疫疗法：急性髓系白血病和骨髓增生异常综合征中的治疗协同作用

Front Oncol. 2021 Feb 25;11:624742. doi: 10.3389/fonc.2021.624742. eCollection 2021.

The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.低甲基化剂对老年骨髓增生异常综合征患者的治疗费用和生存的影响。

Leuk Res. 2012 Nov;36(11):1370-5. doi: 10.1016/j.leukres.2012.07.020. Epub 2012 Aug 20.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.行动呼吁：增加未经治疗的高危骨髓增生异常综合征患者在一线临床试验中的入组率。

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31.

引用本文的文献

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。

Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol.白血病细胞对5-氮杂胞苷的耐药性：对相同诱导方案的不同反应。

Cancers (Basel). 2023 Jun 5;15(11):3063. doi: 10.3390/cancers15113063.

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.口服依坦硝唑治疗对低甲基化药物难治的高危骨髓增生异常综合征患者。

J Hematol Oncol. 2022 Aug 3;15(1):103. doi: 10.1186/s13045-022-01319-y.

本文引用的文献

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.临床试验中修订 MDS 患者 IWG 2018 血液学反应标准的建议。

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.骨髓增生异常综合征和急性髓系白血病中去甲基化药物失败后的诱导化疗评估。

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.H3B-8800，一种口服小分子剪接调节剂，可诱导剪接体突变型癌症致死。

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。（注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平，以下按照正确药物名给出译文）恩西地平用于治疗突变型复发或难治性急性髓系白血病。

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.异基因造血干细胞移植治疗骨髓增生异常综合征和慢性粒-单核细胞白血病：国际专家小组的建议

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17.

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.通过对编码剪接体蛋白的基因突变进行治疗性靶向，调控白血病的剪接催化作用。

Nat Med. 2016 Jun;22(6):672-8. doi: 10.1038/nm.4097. Epub 2016 May 2.

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.当前预后模型在预测低甲基化药物治疗失败时骨髓增生异常综合征患者预后方面的疗效。

Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.利戈塞替尼与最佳支持治疗用于低甲基化药物治疗失败的高危骨髓增生异常综合征患者（ONTIME）：一项随机、对照、3 期试验。

Lancet Oncol. 2016 Apr;17(4):496-508. doi: 10.1016/S1470-2045(16)00009-7. Epub 2016 Mar 9.

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.BCL-2 蛋白阻断剂能有效诱导高危骨髓增生异常综合征患者祖细胞凋亡。

Leukemia. 2016 Jan;30(1):112-23. doi: 10.1038/leu.2015.179. Epub 2015 Jul 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验